Skip to main content
. 2022 Jun 30;23(13):7261. doi: 10.3390/ijms23137261

Figure 3.

Figure 3

Potential mechanisms of benefit of novel antidiabetic agents in the setting of PCI. PCI, percutaneous coronary intervention; GLP-1 RAs, glucagon-like peptide 1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitors; SGLT-2i, sodium-glucose cotransporter-2 inhibitors; NO, nitric oxide; ROS, reactive oxygen species; EPCs, endothelial progenitor cells; MMPs, matrix metalloprotease; VSMCs, vascular smooth muscular cell.